Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing

 
• By John Davis

Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.

R Francis
Sandoz CEO Richard Francis • Source: Sandoz.

More from R&D

More from Scrip